1. Bowser M, Donahue K, Nesbitt LS, Barnes C. District of Columbia Department of Health HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA) Annual Epidemiology & Surveillance Report, Data Through December 2020. 2022. www.dchealth.dc.gov/hahsta
2. Centers for Disease Control and Prevention, Surveillance Report HIV. 2020. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
3. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveill Suppl Rep. 2021;26:1–81. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. http://wwwn.cdc.gov/dcs/ContactUs/Form
4. Office of Infectious Disease and HIV/AIDS, Policy HHS. Priority Jurisdictions: Phase I. HIV.gov. 2020 [cited 2022 May 18]. https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/jurisdictions/phase-one
5. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection [news release]. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration. 2012. https://aidsinfo.nih.gov/news/1254/fda-approves-first-drug-for-reducing-the-risk-of-sexually-acquired-hiv-infection